Dr. Minghui Zhang is a pioneering researcher and practitioner in the field of immune cell therapy
in China.In 2004,he published a landmark cover article in Nature Immunology,elucidating how
the immune microenvironment can reverse dendritic cell function to maintain immune system
homeostasis. In 2002,he was the first to discover and systematically investigate the bidirectional
anti-tumor effects of the CD8+NKT(vNKT) subpopulation. Since 2010,he has spearheaded the
clinical research and application of vNKT cells,which have demonstrated remarkable efficacy in
treating mid-and late-stage solid tumors. Specifically, the five-year tumor-free rate(clinical cure
rate)for patients with stage III solid tumors following vNKT intervention exceeds 80%. For stage IV
colorectal cancer patients with postoperative liver or lung metastasis,a combination of minimally
invasive local tumor reduction and vNKT intervention has achieved a five-year tumor-free rate of
over 40%. Dr. Zhang has also developed a non-chemical therapeutic approach for chronic diseases, primarily
based on mesenchymal stem cells(MSCs) and intestinal microbiota management. This innovative
method has shown rapid and significant efficacy in treating type 2 diabetes, Hashimoto’s
thyroiditis, inflammatory bowel disease, Alzheimer’s disease, and stroke sequelae, often leading
to functional reversal or functional cure. Building on his extensive research and clinical experience, Dr.Zhang established the Lehe New
Medical Chronic Disease Rehabilitation Centerin China.This center offers a comprehensive suite
of services, including research, diagnosis, treatment, rehabilitation and health management, dedicated to improving the lives of patients with chronic diseases
